{"version":"1.0","type":"link","title":"Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer.","author_name":"Shen S 외","author_url":"https://prs-insight.online/author/Shen%20S","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/87997","thumbnail_width":1200,"thumbnail_height":630}